share_log

Novocure Secures New $400M Non-Dilutive Debt Financing From Pharmakon

Novocure Secures New $400M Non-Dilutive Debt Financing From Pharmakon

Novocure从Pharmakon获得新的4亿美元非稀释性债务融资
Benzinga ·  05/02 07:18

Use of proceeds to fund working capital needs stemming from Novocure's anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure's convertible notes

使用所得款项为Novocure预计在非小细胞肺癌领域上市所产生的营运资金需求提供资金,并在到期时结算Novocure的可转换票据

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发